Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Sodium lactate + sodium chloride + magnesium chloride + calcium chloride + dextrose** is a multi-electrolyte peritoneal dialysis solution marketed as **Delflex** and developed by Baxter Healthcare for intraperitoneal use in patients with chronic kidney failure maintained on peritoneal dialysis. The combination contains dextrose as the principal osmotic agent to promote ultrafiltration across the peritoneal membrane, while sodium, calcium, magnesium, chloride, and lactate help maintain electrolyte and acid-base balance during dialysis. It is a small-molecule combination product used as a dialysis solution rather than a receptor-targeted pharmacologic agent, and has been marketed in multiple formulations including low magnesium and low calcium variants.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium lactate + sodium chloride + magnesium chloride + calcium chloride + dextrose.